Recent Quotes

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex's pipeline includes gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. Vertex also has an expanding research pipeline focused on inflammatory diseases, non-opioid treatments for pain, and genetic and cell therapies for type 1 diabetes and rare diseases.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-07-29
REV		(EXPECTED)2021-07-29

Q1 2021		Est.		Actual		Surprise
EPS		2.690		2.980		0.2900
REV		1.660B		1.724B		64.000M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
VRTX	Vertex Pharmaceuticals	189.00	1.15	0.61%		48.6B

Vertex Pharmaceuticals Frequently Asked Questions

How do I buy Vertex Pharmaceuticals (VRTX) stock?

You can purchase shares of Vertex Pharmaceuticals (NASDAQ: VRTX) through any online brokerage.

View our list of the best stock brokerages.

Who are Vertex Pharmaceuticals's (VRTX) competitors?

Other companies in Vertex Pharmaceuticals’s space includes: Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Amgen (NASDAQ:AMGN), BioNTech (NASDAQ:BNTX) and Natera (NASDAQ:NTRA).

What is the target price for Vertex Pharmaceuticals (VRTX) stock?

The latest price target for Vertex Pharmaceuticals (NASDAQ: VRTX) was reported by Piper Sandler on June 14, 2021. The analyst firm set a price target for 261.00 expecting VRTX to rise to within 12 months (a possible 38.94% upside). 34 analyst firms have reported ratings in the last year.

Current Stock Price for Vertex Pharmaceuticals (VRTX)?

The stock price for Vertex Pharmaceuticals (NASDAQ: VRTX) is $187.85 last updated Fri Jun 18 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does Vertex Pharmaceuticals (VRTX) pay a dividend?

There are no upcoming dividends for Vertex Pharmaceuticals.

When is Vertex Pharmaceuticals (NASDAQ:VRTX) reporting earnings?

Vertex Pharmaceuticals’s Q2 earnings are confirmed for after-market on July 29, 2021.

Is Vertex Pharmaceuticals (VRTX) going to split?

There is no upcoming split for Vertex Pharmaceuticals.

What sector and industry does Vertex Pharmaceuticals (VRTX) operate in?

Vertex Pharmaceuticals is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.